文献速递心外重症与机械循环支持

体重指数对左心室辅助装置植入后不良事件的影响:IMACS登记分析

Impact of body mass index on adverse events after implantation of left ventricular assist devices: An IMACS registry analysis.
PubMed 文献 · J Heart Lung Transplant · 2018-06-21

基于IMACS登记中2013至2015年9408例连续流左心室辅助装置(CF-LVAD)植入患者,按术前BMI分为低体重、非肥胖、肥胖和病态肥胖四组。2年生存率四组相似(70.8%至75.8%,p=0.24),但肥胖和病态肥胖组感染及装置相关不良事件更多,装置故障无事件率更低。

要点

  • BMI与CF-LVAD术后2年死亡率无关。
  • 肥胖和病态肥胖患者感染及装置相关不良事件风险更高。
  • 低体重患者血栓栓塞事件虽罕见但更常见。

核心结论

  • BMI与CF-LVAD术后2年死亡率不相关,但肥胖和病态肥胖患者感染及装置相关不良事件增加。

研究设计与样本

  • 基于ISHLT IMACS登记的回顾性分析,纳入2013至2015年9408例连续流左心室辅助装置植入患者。

主要发现

  • 四组BMI患者2年生存率相似(70.8%至75.8%,p=0.24)。
  • 病态肥胖患者2年无感染生存率较低:非VAD相关感染50.3%,装置相关感染70.7%。
  • 低体重(81.5%)和非肥胖(81.3%)患者2年无装置故障率高于肥胖(78.3%)和病态肥胖(72.6%)(p=0.0006)。
  • 血栓栓塞事件罕见,低体重组更常见(p=0.026)。

关键数值与推荐

  • BMI分组:低体重≤18.5 kg/m2;非肥胖>18.5至<30 kg/m2;肥胖≥30至<40 kg/m2;病态肥胖≥40 kg/m2。
  • 不良事件包括感染、血栓栓塞事件、出血、装置故障和神经功能障碍。

临床怎么用

  • 对肥胖和病态肥胖患者植入LVAD后应加强感染监测与预防。
  • 低体重患者需关注血栓栓塞风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data exist describing impact of body mass index (BMI) on post‒left ventricular assist device (post-LVAD) outcomes. We sought to define the relationship between body mass index (BMI) and adverse events (AEs) after LVAD implantation by examining the ISHLT Mechanically Assisted Circulatory Support (IMACS) registry. METHODS: Patients implanted with a contemporary continuous flow (CF)-LVAD were stratified into 4 groups using pre-operative BMI: underweight (UW; BMI ≤18.5 kg/m2); non-obese (NO; BMI >18.5 to <30 kg/m2); obese (OB; BMI ≥30 to <40 kg/m2); and morbidly obese (MO; BMI ≥40 kg/m2). Freedom from AEs was evaluated using the Kaplan-Meier method and risk factors for development of first AE were identified using multiphase parametric hazard modeling. AEs included infection, thromboembolic events, bleeding, device malfunction, and neurologic dysfunction. RESULTS: Between 2013 and 2015, a total of 9,408 patients underwent implantation of a CF-LVAD, which consisted of 368 (4%) UW, 5,719 (61%) NO, 2,770 (29%) OB, and 444 (5%) MO patients. Survival among the 4 BMI cohorts was similar at 2years (70.8% to 75.8%, p = 0.24). MO patients were less likely to be free from a non‒VAD-related infection (p < 0.0001) or device-related infection (p = 0.0014) at 2years (50.3%, 70.7%) when compared with OB (58.3%, 78.7%), NO (65.2%, 81.4%), and UW (68.9%, 77.4%) patients. UW (81.5%) and NO (81.3%) patients were more likely to be free from device malfunction at 2years when compared with OB (78.3%) and MO (72.6%) (p = 0.0006). Thromboembolic events were rare and more common in the UW cohort (p = 0.026). CONCLUSIONS: Although BMI was not correlated with 2-year mortality, an increased rate of infectious and device-related AEs was noted in OB and MO LVAD patients. In a group with few options for transplant, the event morbidity in obese patients can be expected to impact morbidity with longer support durations.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Forest SJ, Xie R, Kirklin JK, et al. Impact of body mass index on adverse events after implantation of left ventricular assist devices: An IMACS registry analysis. J Heart Lung Transplant. 2018. PMID: 30195832. doi:10.1016/j.healun.2018.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。